Breaking News

Financial Report: Baxter

January 24, 2013

BioScience revenues up 7% in the quarter

Baxter
 
4Q Revenues:
$3.8 billion (+4%)

4Q Earnings: $494 million (+7%)

YTD Revenues: $14.2 billion (+2%)

YTD Earnings: $2.3 billion (+5%)

Comments: BioScience revenues were $1.7 billion in the quarter, up 7%. U.S. sales were $1.6 billion, up 7%, driven by sales growth for Advate, and Gammagard Liquid, as well as other plasma-based therapeutics. International sales were up 2% to $2.2 billion. Medical Products sales were $2.1 billion, up 2%, driven primarily by gains in peritoneal dialysis patients in the U.S., as well as growth in intravenous therapies. Results in the quarter included special after-tax items of $206 million related to costs associated with settlement of certain U.S. pension obligations and business optimization initiatives.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision